Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small-cell Lung Cancer
Conditions
Extensive-stage Small-cell Lung Cancer
Trial Timeline
Feb 3, 2025 → Mar 1, 2029
NCT ID
NCT06712355About Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)
Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated) is a phase 3 stage product being developed by Bristol Myers Squibb for Extensive-stage Small-cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06712355. Target conditions include Extensive-stage Small-cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06712355 | Phase 3 | Recruiting |
Competing Products
20 competing products in Extensive-stage Small-cell Lung Cancer